Cargando…

Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment

INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkins, Ryan C., Davies, Mark R., Brough, Stephen J., Gavaghan, David J., Cui, Yi, Abi-Gerges, Najah, Mirams, Gary R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135079/
https://www.ncbi.nlm.nih.gov/pubmed/23651875
http://dx.doi.org/10.1016/j.vascn.2013.04.007
_version_ 1782330934914187264
author Elkins, Ryan C.
Davies, Mark R.
Brough, Stephen J.
Gavaghan, David J.
Cui, Yi
Abi-Gerges, Najah
Mirams, Gary R.
author_facet Elkins, Ryan C.
Davies, Mark R.
Brough, Stephen J.
Gavaghan, David J.
Cui, Yi
Abi-Gerges, Najah
Mirams, Gary R.
author_sort Elkins, Ryan C.
collection PubMed
description INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. METHODS: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of I(Kr) (hERG), I(Na) (NaV1.5), I(CaL) (CaV1.2), I(Ks) (KCNQ1/minK) and I(to) (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for I(CaL) (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. RESULTS: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound’s ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. DISCUSSION: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound’s action to acceptable levels, to allow a meaningful interpretation of the data.
format Online
Article
Text
id pubmed-4135079
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-41350792014-08-18 Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment Elkins, Ryan C. Davies, Mark R. Brough, Stephen J. Gavaghan, David J. Cui, Yi Abi-Gerges, Najah Mirams, Gary R. J Pharmacol Toxicol Methods Article INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. METHODS: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of I(Kr) (hERG), I(Na) (NaV1.5), I(CaL) (CaV1.2), I(Ks) (KCNQ1/minK) and I(to) (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for I(CaL) (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. RESULTS: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound’s ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. DISCUSSION: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound’s action to acceptable levels, to allow a meaningful interpretation of the data. 2013-05-05 2013 /pmc/articles/PMC4135079/ /pubmed/23651875 http://dx.doi.org/10.1016/j.vascn.2013.04.007 Text en © 2013 The Authors. Published by Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Elkins, Ryan C.
Davies, Mark R.
Brough, Stephen J.
Gavaghan, David J.
Cui, Yi
Abi-Gerges, Najah
Mirams, Gary R.
Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title_full Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title_fullStr Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title_full_unstemmed Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title_short Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
title_sort variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135079/
https://www.ncbi.nlm.nih.gov/pubmed/23651875
http://dx.doi.org/10.1016/j.vascn.2013.04.007
work_keys_str_mv AT elkinsryanc variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT daviesmarkr variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT broughstephenj variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT gavaghandavidj variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT cuiyi variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT abigergesnajah variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment
AT miramsgaryr variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment